

Version March 2025

| Gene panels | Alias | Turnaround time | Prices € |
|---|----------------------------|-----------------|----------|
| <i>See next pages for request of individual genes</i> | | | |
| ○ Basal cell carcinoma | BCC panel | 56 days | 1200 |
| ○ Breast and ovarium cancer panel | HBOC panel | 42 days | 1200 |
| ○ Cerebral angiopathies / adult-onset leukoencephalopathies (including CADASIL) | CHA panel | 90 days | 1500 |
| ○ Coffin-Siris / Nicolaides-Baraitser syndrome | CSS panel | 90 days | 1500 |
| ○ Colorectal carcinoma | CRC panel | 70 days | 1500 |
| ○ Episodic Ataxia | EA panel | 56 days | 1500 |
| ○ FAMMM (Familial Atypical Multiple Mole-Melanoma) | Melanoma panel | 56 days | 1200 |
| ○ Familial pancreatic carcinoma | PACA panel | 42 days | 1500 |
| ○ Short stature, basic gene panel | Growth panel | 56 days | 1500 |
| ○ Hereditary Multiple Osteochondromas | HMO panel | 56 days | 1500 |
| ○ LYNCH syndrome | LYNCH panel | 56 days | 1200 |
| ○ Lipodystrophy | LIPO panel | 90 days | 1500 |
| ○ Migraine, familial hemiplegic | FHM panel | 56 days | 1500 |
| ○ MODY (Maturity Onset Diabetes of the Young) | Diabetes panel MODYScan | 90 days | 1500 |
| ○ Muscular dystrophies / myopathies | Muscle panel MuscleScan | 56 days | 1500 |
| ○ Paragangliomas and/or pheochromocytomas | PGL panel | 56 days | 1200 |
| ○ Polyglutamin repeat disorders | PolyQ | 56 days | 650 |
| ○ Polyposis coli, adenomatous* | Polyp panel | 56 days | 1200 |
| ○ Polycystic kidney disease | PKD panel | 90 days | 1500 |
| ○ Skeletal Muscle Channelopathies | Channelopathies | 56 days | 1500 |

For an overview of all genes in the gene panels see <https://www.lumc.nl/over-het-lumc/afdelingen/klinische-genetica/genpanels/>

| Disorder/Referral | Type | Gene/Test | Turnaround time | Prices € |
|---|--------|--|---------------------------|--------------|
| Blood diseases | | | | |
| ○ Hemochromatosis | Type 1 | ○ HFE | 28 days | 350 |
| ○ Hemoglobinopathies / Thalassemia Please use "Requisition form Hemoglobinopathy analysis" | | | | 750 |
| ○ Hemophilia (Please send in 2 tubes of EDTA blood) | Type A | ○ F8 | 56 days | 650 |
| | Type B | ○ F9 | 56 days | 550 |
| Cancer genetics | | | | |
| <i>*Requests only by a consultant clinical geneticist</i> | | | | |
| ○ Breast- and ovarian cancer, hereditary * | | ○ ATM | 56 days | 550 |
| | | ○ BARD1 | 56 days | 550 |
| | | ○ BRCA1 | 56 days | 750 |
| | | ○ BRCA2 | 56 days | 750 |
| | | ○ BRIP1 | 56 days | 550 |
| | | ○ CHEK2 | 56 days | 550 |
| | | ○ PALB2 | 56 days | 550 |
| | | ○ RAD51C | 56 days | 550 |
| | | ○ RAD51D | 56 days | 550 |
| ○ Clear cell meningioma/ Familial Multiple Meningioma* | CCM | ○ SMARCE1 | 56 days | 750 |
| | | ○ SMARCB1 | 56 days | 750 |
| ○ FAMMM (Familial Atypical Multiple Mole-Melanoma)* | | ○ CDKN2A | 56 days | 350 |
| | | ○ CDK4 | 56 days | 350 |
| | | ○ POT1 | 56 days | 550 |
| | | ○ BAP1 | 56 days | 550 |
| | | ○ MITF | 56 days | 350 |
| ○ Gastrointestinal Stromal Tumors (GIST, Carney-Stratakis syndrome) | | ○ SDHA | 56 days | 550 |
| ○ Hyperparathyroidism-jaw tumor syndrome (HPT-JT/HRPT2) | | ○ CDC73 | 56 days | 750 |
| ○ Lynch syndrome (HNPCC)* | | ○ MLH1 | 56 days | 750 |
| | | ○ MSH2 (incl. EPCAM) | 56 days | 750 |
| | | ○ MSH6 | 56 days | 750 |
| | | ○ PMS2 | 56 days (RNA 120 days) | 750 (750) |
| ○ Myeloproliferative diseases (MPDs, somatic mutation) | | ○ JAK2 (p.Val617Phe) | 28 days | 350 |
| | | ○ MPN-combi: JAK2 exon 12 & exon 14 p.(Val617Phe), MPL exon 10 and CALR exon 9 | 28 days | 350 |
| ○ Parangliomas and/or pheochromocytomas | | ○ MAX | 56 days | 550 |

| | | | | |
|--|---------|----------------------------|---------|-----|
| | | ○ SDHA | 56 days | 550 |
| | | ○ SDHAF2 | 56 days | 750 |
| | | ○ SDHB | 56 days | 750 |
| | | ○ SDHC | 56 days | 750 |
| | | ○ SDHD | 56 days | 750 |
| | | ○ TMEM127 | 56 days | 550 |
| ○ Polyposis coli, adenomatous* | FAP1 | ○ APC (incl. GREM1) | 56 days | 900 |
| | MAP | ○ MUTYH | 56 days | 750 |
| | NAP | ○ NTHL1 | | 550 |
| | PPAP | ○ POLD1 | 56 days | 550 |
| | PPAP | ○ POLE | 56 days | 550 |
| | FAP4 | ○ MSH3 | 56 days | 650 |
| ○ Renal Cell Carcinoma (RCC), hereditary | | ○ SDHB | 56 days | 750 |
| ○ Rhabdoid tumor predisposition syndrome (RTPS)* | RTPS1 | ○ SMARCB1 | 56 days | 750 |
| | RTPS2 | ○ SMARCA4 | 56 days | 650 |
| ○ Small cell carcinoma of the ovary, hypercalcemic type* | SCCOHT | ○ SMARCA4 | 56 days | 650 |
| | SCCOHT | ○ SMARCB1 | 56 days | 750 |
| ○ Schwannomatosis* | | ○ SMARCB1 | 56 days | 750 |
| Channelopathies | | | | |
| ○ Hyperkalemic periodic paralysis (HYPP) | | ○ SCN4A | 56 days | 750 |
| ○ Hypokalemic periodic paralysis (HOKPP) | Type 1 | ○ CACNA1S | 28 days | 750 |
| | Type 2 | ○ SCN4A | 56 days | 750 |
| ○ Myotonia congenita (Thomsen, Becker disease) | | ○ CLCN1 | 56 days | 750 |
| ○ Myotonia permanens/fluctuans | | ○ SCN4A | 56 days | 750 |
| ○ Paramyotonia congenita | | ○ SCN4A | 56 days | 750 |
| Diabetes | | | | |
| ○ Hyperproinsulinemia | | ○ INS | 56 days | 750 |
| ○ Insulin dependent diabetes | | ○ INS | 56 days | 750 |
| ○ MIDD (Maternally Inherited Diabetes and Deafness) | | ○ m.3243A>G tRNALEU/UUR | 28 days | 750 |
| ○ MODY (Maturity Onset Diabetes of the Young) | Type 1 | ○ HNF4A | 56 days | 750 |
| | Type 2 | ○ GCK | 56 days | 750 |
| | Type 3 | ○ HNF1A | 56 days | 750 |
| | Type 4 | ○ PDX1 (IPF1) | 56 days | 750 |
| | Type 5 | ○ HNF1B | 56 days | 750 |
| | Type 6 | ○ NEUROD1 | 56 days | 750 |
| | Type 10 | ○ INS | 56 days | 750 |
| ○ PNDM (Permanent Neonatal Diabetes Mellitus) | | ○ GCK | 56 days | 750 |
| | | ○ INS | 56 days | 750 |
| | | ○ KCNJ11 | 56 days | 750 |
| ○ Persistent hyperinsulinemic hypoglycemia of infancy (PHHI) | | ○ GCK | 56 days | 750 |

| | | | | |
|---|----------------|----------------|---------|-----|
| | | ○ KCNJ11 | 56 days | 750 |
| Growth and skeletal defects | | | | |
| ○ Achondroplasia | | ○ FGFR3 | 56 days | 750 |
| ○ Acromesomelic dysplasia | Type Maroteaux | ○ NPR2 | 56 days | 750 |
| ○ Hereditary Multiple Osteochondromas | | ○ EXT1 | 56 days | 750 |
| | | ○ EXT2 | 56 days | 750 |
| ○ NPR2- related tall stature | | ○ NPR2 | 56 days | 750 |
| ○ Hypochondroplasia | | ○ FGFR3 | 56 days | 650 |
| ○ Langer mesomelic dysplasia (Leri-Weill dyschondrosteosis) | | ○ SHOX | 56 days | 750 |
| ○ Multiple epiphyseal dysplasia | | ○ COMP | 56 days | 550 |
| ○ Pseudoachondroplastic dysplasia | | ○ COMP | 56 days | 550 |
| ○ Short stature (proportionate) | | ○ GH1 | 56 days | 750 |
| | | ○ GHR | 56 days | 750 |
| | | ○ GHSR | 56 days | 550 |
| | | ○ IGF1 | 56 days | 750 |
| | | ○ IGF1R | 56 days | 750 |
| | | ○ IGFALS | 56 days | 750 |
| | | ○ STAT5B | 56 days | 750 |
| ○ Short stature (osteochondritis dissecans) | | ○ ACAN | 56 days | 650 |
| ○ Tall stature | | ○ NPR2 | 56 days | 750 |
| ○ Thanatophoric dysplasia | | ○ FGFR3 | 56 days | 650 |
| ○ Van Buchem disease | | ○ VBCH | 28 days | 750 |
| Immune system | | | | |
| ○ Chilblain lupus | Type 1 | ○ TREX1 | 28 days | 550 |
| ○ Granulomatous disease, chronic, X-linked | | ○ CYBB | 56 days | 550 |
| ○ Lymphoproliferative syndrome, X-linked | | ○ XLP | 28 days | 550 |
| ○ Mediterranean fever, familial (FMF) | | ○ MEFV | 56 days | 550 |
| ○ Wiskott-Aldrich syndrome | | ○ WAS | 28 days | 550 |
| Metabolic diseases | | | | |
| ○ Adrenal hypoplasia, congenital | | ○ NROB1 (DAX1) | 56 days | 750 |
| ○ Cystinuria | | ○ SLC3A1 | 56 days | 550 |
| | | ○ SLC7A9 | 56 days | 550 |
| Muscular dystrophies/ Myopathies | | | | |
| ○ Slow-channel congenital myasthenic syndrome-4A (CMS4A) | Type 4A | ○ CHRNE | 56 days | 350 |
| ○ Congenital myasthenic syndrome-5 (CMS5) | Type 5 | ○ COLQ | 56 days | 350 |
| ○ Congenital myasthenic syndrome-9 (CMS9) associated with AChR deficiency | Type 9 | ○ MUSK | 56 days | 350 |
| ○ Congenital myasthenic syndrome-10 (CMS10) | Type 10 | ○ DOK7 | 56 days | 350 |

| | | | | |
|---|--|---|---------|------------|
| ○ Congenital myasthenic syndrome-11 associated with acetylcholine receptor deficiency (CMS11) | Type 11 | ○ RAPSN | 56 days | 350 |
| ○ Congenital myasthenic syndrome-14 (CMS14) | Type 14 | ○ ALG2 | 56 days | 350 |
| ○ Congenital myasthenic syndrome-15 (CMS15) | Type 15 | ○ ALG14 | 56 days | 350 |
| ○ Duchenne and Becker | | ○ DMD MLPA only | 28 days | 350 |
| | | ○ DMD Sequencing only | 56 days | 650 |
| | | ○ DMD MLPA, if negative directly followed by sequencing | 56 days | 350 or 900 |
| ○ Emery-Dreifuss (X-linked) | | ○ EMD | 28 days | 550 |
| ○ Facioscapulohumeral (FSHD) (Please send in 2 tubes of EDTA blood) | Type 1/2 | ○ Rearrangement chromosome 4 | 90 days | 1000 |
| | | ○ Permissive haplotype analysis (4qA/B) | 90 days | 1000 |
| | Type 2 | ○ SMCHD1 | 56 days | 750 |
| | | ○ LRIF1 | 56 days | |
| | | ○ DNMT3B | 56 days | |
| ○ Limb Girdle | Myofibrillar myopathy | ○ MYOT | 56 days | 550 |
| | Emery–Dreifuss muscular dystrophy (EDMD) | ○ LMNA | 56 days | 550 |
| | Rippling muscle disease | ○ CAV3 | 28 days | 550 |
| | LGMD D4 / R1 | ○ CAPN3 | 56 days | 750 |
| | LGMD R2 | ○ DYSF | 56 days | 750 |
| | LGMD R5 | ○ SGCG | 56 days | 550 |
| | LGMD R3 | ○ SGCA | 56 days | 550 |
| | LGMD R4 | ○ SGCB | 56 days | 550 |
| | LGMD R6 | ○ SGCD | 56 days | 550 |
| | LGMD R7 | ○ TCAP | 28 days | 550 |
| | LGMD R8 | ○ TRIM32 | 56 days | 550 |
| | LGMD R9 | ○ FKRP | 28 days | 550 |
| | LGMD R12 | ○ ANO5 | 56 days | 550 |
| ○ Miyoshi (MMD3) | | ○ ANO5 | 56 days | 550 |
| ○ Myopathy with extrapyramidal signs | | ○ MICU1 | 28 days | 550 |
| | | | | |

| | | | | |
|--|------------------------|--|---------|-----|
| Neurogenetics | | | | |
| ○ Aicardi-Goutières syndrome | Type 1 | ○ TREX1 | 28 days | 550 |
| ○ Alternating Hemiplegia of Childhood | Type 2 | ○ ATP1A3 | 56 days | 550 |
| ○ CADASIL | | ○ NOTCH3 | 56 days | 650 |
| ○ CARASIL/ CADASIL | Type 2 | ○ HTRA1 | 56 days | 650 |
| ○ Cerebral hemorrhage with amyloidosis (HCHWA-D) | | ○ APP | 28 days | 350 |
| ○ Dentatorubral-pallidoluysian atrophy (DRPLA) | | ○ ATN1 | 28 days | 350 |
| ○ Episodic ataxia | Type 2 | ○ CACNA1A | 56 days | 750 |
| ○ Huntington disease | | ○ HTT | 28 days | 350 |
| ○ Huntington, disease-like 2 (HDL2) | | ○ JPH3 | 28 days | 350 |
| ○ Hyperekplexia (familial Startle disease) | | ○ GLRA1 | 56 days | 750 |
| | | ○ GLRB | 56 days | 750 |
| | | ○ SLC6A5 | 56 days | 750 |
| ○ Migraine, familial hemiplegic (FHM) | | ○ ATP1A2 | 56 days | 750 |
| | | ○ CACNA1A | 56 days | 750 |
| | | ○ SCN1A | 56 days | 750 |
| ○ Myoclonus dystonia syndrome | | ○ SGCE | 56 days | 750 |
| ○ Neuronal ceroid lipofuscinosis (NCL) | Juvenile | ○ CLN3 | 56 days | 550 |
| | Late infantile | ○ TPP1 (CLN2) | 56 days | 550 |
| | Late infantile | ○ CLN6 | 56 days | 550 |
| | Late infantile | ○ CLN8 | 56 days | 550 |
| | Late infantile / adult | ○ PPT1 (CLN1) | 56 days | 550 |
| ○ Paroxysmal torticollis | | ○ CACNA1A | 56 days | 750 |
| ○ Polyglutamin repeat disorders | | ○ CACNA1A, TBP, ATXN1, ATXN7, ATXN2, ATXN3 en ATN1 | 56 days | 650 |
| ○ Retinal vasculopathy with cerebral leukodystrophy (RVCL) | | ○ TREX1 | 28 days | 550 |
| Polycystic kidney disease | | | | |
| ○ Autosomal dominant Polycystic kidney disease (ADPKD) | Dominant | ○ PKD1 | 90 days | 900 |
| | Dominant | ○ PKD2 | 56 days | 750 |
| ○ Autosomal dominant Polycystic kidney and liver disease (ADPKD) | Dominant | ○ GANAB | 56 days | 750 |
| ○ Autosomal recessive Polycystic kidney (ARPKD) | Recessive | ○ PKHD1 | 56 days | 900 |
| ○ Renal cysts and diabetes syndrome (RCAD) | Dominant | ○ HNF1B | 56 days | 750 |
| Syndromes | | ○ | | |
| ○ Coffin-Siris syndrome | | ○ ARID1A | 56 days | 750 |
| | | ○ ARID1B | 56 days | 750 |
| | | ○ SMARCA4 | 56 days | 650 |
| | | ○ SMARCB1 | 56 days | 550 |
| | | ○ SMARCE1 | 56 days | 550 |

| | | | | |
|---|--|---------------------------------|---------|---------------------|
| ○ Ellis van Creveld syndrome | | ○ EVC | 56 days | 550 |
| | | ○ EVC2 | 56 days | 550 |
| ○ Filippi syndrome | | ○ CKAP2L | 56 days | 550 |
| ○ Marshall-Smith syndrome | | ○ NFIX | 56 days | 750 |
| ○ Nicolaides-Baraitser syndrome | | ○ SMARCA2 | 56 days | 650 |
| ○ Peters Plus syndrome | | ○ B3GLCT (B3GALTL) | 56 days | 750 |
| ○ Pitt-Hopkins syndrome | | ○ TCF4 | 56 days | 750 |
| ○ Rubinstein - Taybi syndrome | | ○ CREBBP | 56 days | 750 |
| | | ○ EP300 | 56 days | 750 |
| ○ Sotos syndrome | | ○ NSD1 | 56 days | 750 |
| ○ Sotos-like syndrome | | ○ DNMT3A | 56 days | 550 |
| | | ○ NFIX | 56 days | 750 |
| | | ○ SETD2 | 56 days | 650 |
| | | ○ HIST1H1E | 56 days | 550 |
| ○ TAR (thrombocytopenia-absent radius) syndrome | | ○ 1q21.1 deletion and RBM8A SNP | 28 days | 550 |
| ○ Weaver syndrome | | ○ EZH2 | 56 days | 550 |
| Other | | | | |
| ○ Hypocalciuric Hypercalcemia, Familial (FHH) | | ○ CASR ○ GNA11 ○ AP2S1 | 56 days | 550 3 genes 1500 |
| ○ Keratosis follicularis spinulosa decalvans (KFSD) | | ○ MBTPS2 | 28 days | 550 |